BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET
Company Participants
Alexander Hardy – President, CEO & Director
Brian R. Mueller – Executive VP of Finance & CFO
Cristin Hubbard – Executive VP & Chief Commercial Officer
Gregory Friberg – Executive VP and Chief Research & Development Officer
Traci McCarty – Group Vice President
Conference Call Participants
Akash Tewari – Jefferies LLC, Research Division
Alexandria Janet Hammond – Wolfe Research, LLC
Allison Marie Bratzel – Piper Sandler & Co., Research Division
Cory William Kasimov – Evercore ISI Institutional Equities, Research Division
Ellen Horste – TD Cowen, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Jasmine Alexandra Fels – UBS Investment Bank, Research Division
Jason Matthew Gerberry – BofA Securities, Research Division
Konstantinos Biliouris – BMO Capital Markets Equity Research
Olivia Simone Brayer – Cantor Fitzgerald & Co., Research Division
Paul Andrew Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Sean M. Laaman – Morgan Stanley, Research Division
Tommie M. Reerink – Goldman Sachs Group, Inc., Research Division
Operator
Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceuticals Second Quarter 2025 Conference Call. Today’s conference is being recorded. [Operator Instructions]
At this time, I would like to turn the conference over to Traci McCarty, Investor Relations at BioMarin. Please go ahead.
Traci McCarty
Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and
#BioMarin #Pharmaceutical #BMRN #Earnings #Call #Transcript